Sign in Subscribe
Allergens

Long-Term Study Reveals Remission as Preferred Outcome over Desensitization in Food Allergy Immunotherapy

Strategic Insights

— 1 min read

A recent study published in the journal Allergy has found that remission is a preferred outcome over desensitization in food allergy immunotherapy. The Phase 2b study, conducted by Prota Therapeutics Pty Ltd, directly compared the long-term benefits and risks associated with remission and desensitization in children who received high-dose peanut oral immunotherapy treatments. The study found that participants who achieved remission reported fewer peanut ingestion reactions, improved quality of life, and were able to stop treatment and safely consume peanuts freely.

Key Takeaways:

  • The study, published in the journal Allergy, directly compared the long-term benefits and risks associated with remission and desensitization in children who received high-dose peanut oral immunotherapy treatments.
  • Remission was achieved in 51% of participants treated with PRT120, a standalone high-dose OIT, and in 46% of participants treated with PRT100, a probiotic OIT combination treatment.
  • Participants who achieved remission reported significantly improved quality of life, reduced reactions, and no moderate or severe reactions or rescue epinephrine injector use.
  • In contrast, participants who only achieved desensitization experienced difficulty maintaining their required daily peanut ingestion dose, reported severe reactions, and did not experience any improvement in quality of life.
  • Both PRT120 and PRT100 treatments provided lasting benefits that persisted or improved during the 2-year period after stopping treatment.
  • Children who received either PRT120 or PRT100 experienced fewer reactions over time and enjoyed significantly improved health-related quality of life (HRQOL) compared to the placebo group.

Statistics:

  • 51% of participants treated with PRT120 achieved remission.
  • 46% of participants treated with PRT100 achieved remission.
  • 2-year post-treatment outcomes showed that children who received either PRT120 or PRT100 experienced fewer reactions over time.
  • Participants who achieved remission reported no moderate or severe reactions or rescue epinephrine injector use.
  • The study validated remission as a preferred outcome to desensitization.

Sources:

  • Prota Therapeutics Pty Ltd (NewsRx, 2024). Prota Therapeutics Announces Publication of First Long-Term Study Directly Comparing Remission and Desensitization Endpoints Following Food Allergen Oral Immunotherapy (OIT) [News Release].
  • NewsRx (2024). Prota Therapeutics Announces Publication of First Long-Term Study Directly Comparing Remission and Desensitization Endpoints Following Food Allergen Oral Immunotherapy (OIT) [News Release].

Read more